SCHEMBL5333059

SCHEMBL5333059

CCCCCOc1cncc([N+](=O)[O-])c1C(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.43
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PLA2G4B P0C869 1/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CYP19A1 P11511 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 2/20 0.37
APAF1 O14727 1/20 0.37
NTSR1 P30989 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10107524 0.76 NPC1 (0.42) ESR1SMN1; SMN2LMNAMAPTNPSR1
SCHEMBL10107525 0.75 PDE4A (0.51) ESR1SMN1; SMN2LMNAMAPTNPSR1
SCHEMBL28748738 0.73 THRA (0.65) ESR1THRATHRBLMNAMAPT
SCHEMBL5333051 0.73 ESR1 (0.50) ESR1THRATHRBSMN1; SMN2LMNA
SCHEMBL8595772 0.73 LMNA (0.50) THRATHRBSMN1; SMN2LMNAMAPT
SCHEMBL2313353 0.72 THRA (0.67) ESR1THRATHRBLMNAMAPT
SCHEMBL6870341 0.72 AKR1C3 (0.56) ESR1THRATHRBPLA2G4BAKR1C3
SCHEMBL27795167 0.72 SMN1; SMN2 (0.52) THRATHRBSMN1; SMN2LMNAMAPT
SCHEMBL26651124 0.72 HTT (0.53) ESR1THRATHRBLMNAMAPT
SCHEMBL8596253 0.69 CYP19A1 (0.40) THRATHRBSMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135459-A1 Substituted 7-aza-quinazoline compounds useful as p38 kinase inhibitors DEWDNEY NOLAN J 2007-06-14 US disclosed
US-7189731-B2 Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
EP-1620105-B1 (6-(PHENOXY)-PYRIDO¬3,4-D|PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS SUCH AS RHEUMATOID ARTHRITIS HOFFMANN LA ROCHE (CH) 2007-01-10 EP disclosed
EP-1620105-A1 (6-(PHENOXY)-PYRIDO[3,4-D]PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS SUCH AS RHEUMATOID ARTHRITIS F. HOFFMANN-LA ROCHE AG (CH) 2006-02-01 EP disclosed
WO-2004091625-A1 (6-(PHENOXY)-PYRIDO`3,4-D! PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORYY CONDITIONS SUCH AS RHEUMATOIS ARTRITIS F. HOFFMANN-LA ROCHE AG (CH) 2004-10-28 WO disclosed
US-20040209903-A1 Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors ROCHE PALO ALTO LLC 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135459-A1 Substituted 7-aza-quinazoline compounds useful as p38 kinase inhibitors MAPK7, MAPK1, MAPK8 ESR1 3701/4885THRA 2713/4885THRB 2160/4885
US-20040209903-A1 Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors MAPK1, MAPK7, MAPK6 ESR1 4096/4885THRA 3324/4885THRB 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.